SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ISIS?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: RICHARD LOCKIE5/25/1996 11:06:00 PM
   of 30
 
Patent award

I read that Isis Pharmaceuticals received a US patent for ISIS 2302, an antisense inhibitor of intercellular adhesion molecule-1. ISIS 2302 is currently in Phase 2 clinical trials as a treatment for a wide range of inflammatory diseases and conditions. Comments taken from
PR Newswire.

Richard Lockie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News